Scheriproct Suppositories
- Name:
Scheriproct Suppositories
- Company:
Karo Pharma AB
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 29/01/21
(Click to Download)Click on this link to Download PDF directly
Karo Pharma AB
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name Burinex 1 mg Tablets | Active Ingredients Bumetanide |
| Medicine Name Burinex 5 mg Tablets | Active Ingredients Bumetanide |
| Medicine Name Centyl K Tablets | Active Ingredients Bendroflumethiazide, Potassium Chloride |
| Medicine Name Low Centyl K | Active Ingredients Bendroflumethiazide, Potassium Chloride |
| Medicine Name Pivmecillinam hydrochloride Karo Pharma 400 mg film-coated tablets | Active Ingredients Pivmecillinam Hydrochloride |
| Medicine Name Scheriproct Rectal Ointment | Active Ingredients Cinchocaine hydrochloride, prednisolone caproate |
| Medicine Name Scheriproct Suppositories | Active Ingredients Cinchocaine hydrochloride, prednisolone caproate |
| Medicine Name Ultraproct | Active Ingredients Cinchocaine hydrochloride, Fluocortolone caproate, Fluocortolone pivalate |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 29 January 2021 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change of Marketing Authorisation Holder
Updated on 29 January 2021 PIL
Reasons for updating
- Change of licence holder
Free text change information supplied by the pharmaceutical company
Change of Marketing Authorisation Holder
Updated on 7 January 2020 SPC
Reasons for updating
- Addition of marketing authorisation holder
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 7 January 2020 PIL
Reasons for updating
- Change to marketing authorisation holder
Updated on 8 August 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 21 May 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 21 May 2019 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated SPC to include new PRAC update on vision
Section 4.4
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of
possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Section 4.8
Eye disorders
Blurred vision may occur, however the frequency is not known (see also section 4.4).
Updated on 8 February 2018 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The excipient (hard fat) in Scheriproct suppositories may reduce the effectiveness of latex products such as condoms.
10. Date of Revision of Text, changed
Updated on 8 February 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 8 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 8 February 2018 PIL
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
The excipient (hard fat) in Scheriproct suppositories may reduce the effectiveness of latex products such as condoms.
10. Date of Revision of Text, changed
Updated on 31 March 2017 PIL
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Added Deleted
4.5. Interaction with other medicinal products and other forms of interaction
None so far known.
No interaction studies have been performed.
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
10. DATE OF REVISION OF THE TEXT
September 2014 March 2017
Updated on 31 March 2017 SPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Added Deleted
4.5. Interaction with other medicinal products and other forms of interaction
None so far known.
No interaction studies have been performed.
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
10. DATE OF REVISION OF THE TEXT
September 2014 March 2017
Updated on 22 January 2015 SPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 22 January 2015 PIL
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Updated on 11 December 2013 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 11 December 2013 PIL
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Updated on 11 July 2013 PIL
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Free text change information supplied by the pharmaceutical company
Updated on 11 July 2013 SPC
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Legal category: Product subject to medical prescription which may not be renewed (A)